CLASS II Drug recall · Reported 30 Dec 2020 · FDA Enforcement Report

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection recalled

Fresenius Kabi USA is recalling Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per (5 mg, distributed nationwide in the US. The recall was initiated on 10 Dec 2020 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesBatch # 6123760, Exp 02/2022
NDC63323-460, 63323-465, 63323-467, 63323-464, 63323-466, 63323-462
Quantity recalled4411 trays

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0172-2021
FDA event ID
86964
Recalling firm
Fresenius Kabi USA, Lake Zurich, IL
Manufacturer
Fresenius Kabi USA, LLC
Classification
Class II
Status
Terminated
Recall initiated
10 Dec 2020
FDA classified
22 Dec 2020
Reported
30 Dec 2020
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

10 Dec 2020Recall initiated by company
22 Dec 2020Classified by FDA+12 days
30 Dec 2020Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Subpotent Drug: Low out-of-specification assay results for the epinephrine component.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Sensorcaine-MPF (Bupivacaine HCl and Epinephrine Injection, USP), 0.5%, 150 mg per 30 mL (5 mg per mL), 30 mL Single Dose Vial (NDC 63323-462-01), packaged as 25 Single Dose Vials per tray (NDC 63323-462-37), Rx only, Fresenius Kabi, Lake Zurich, IL 60047.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Subpotent Drug: Low out-of-specification assay results for the epinephrine component.

Which lots are affected?

Batch # 6123760, Exp 02/2022

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Fresenius Kabi USA

All 94

Other Bupivacaine Hydrochloride recalls

All 5